Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia

Not Applicable

Completed

• Conditions: S. aureus (meticillin-susceptible or resistant) infection, acute infection; Infections and Infestations; Staphylococcus aureus as the cause of diseases classified to other chapters

• Registration Number: ISRCTN37666216
• Lead Sponsor: Medical Research Council (MRC) (UK)

Brief Summary

2012 protocol in: http://www.ncbi.nlm.nih.gov/pubmed/23249501 2018 results in: http://www.ncbi.nlm.nih.gov/pubmed/30382016

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-01-26
• Study Completion: 2017-01-17
• Last Update Posted: 4 December 2018

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 770

Inclusion Criteria

1. Adults (18 years or older)
2. Staphylococcus aureus (meticillin-susceptible or resistant) grown from at least one blood culture
3. Less than 96 hours of active antibiotic therapy for the current infection (added 09/11/2016: not including rifampicin and excluding stat doses)
4. Patient or legal representative (LR) provides written informed consent

Exclusion Criteria

1. Infection not caused by S. aureus alone in the opinion of the treating physician (e.g. S. aureus is considered a blood culture contaminant, or polymicrobial culture with another organism likely to be contributing clinically to the current infection)
2. Sensitivity results already available and demonstrate rifampicin resistant S. aureus (defined by British Society for Antimicrobial Chemotherapy in vitro disc susceptibility testing)
3. Treating physician considers rifampicin is contraindicated for any reason
4. Treating physician considers rifampicin treatment is mandatory for any reason
5. Suspected active infection with Mycobacterium tuberculosis
6. Previously been randomised in ARREST for a prior episode of S. aureus bacteraemia

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<br> Current primary outcome measures as of 09/11/2016:<br> Bacteriological failure/death through 12 weeks from randomisation<br><br> Previous primary outcome measures:<br> 1. All cause mortality through 14 days from randomisation<br> 2. Bacteriological failure/death through 12 weeks from randomisation<br>